Teva and medincell announce fda acceptance of new drug application for tv-46000/mdc-irm as a treatment for patients with schizophrenia

Parsippany, n.j., tel aviv & paris--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and medincell (euronext: medcl) announced today that the new drug application (nda) for tv-46000/mdc-irm (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the u.s. food and drug administration (fda). the acceptance is based on phase 3 data from two pivotal studies:
TEVA Ratings Summary
TEVA Quant Ranking